Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

Open in Screener

IRD

Opus Genetics Inc

Jan 17 • 04:00PM ET

1.13

Dollar change -0.03
Percentage change -2.59	%

Healthcare • Biotechnology • USA • NASD

Held by: VTI VXF IWC BSVO

Index	-	P/E	-	EPS (ttm)	-1.09	Insider Own	18.28%	Shs Outstand	26.20M	Perf Week	-20.42%
Market Cap	35.67M	Forward P/E	-	EPS next Y	-0.85	Insider Trans	3.78%	Shs Float	25.80M	Perf Month	13.00%
Income	-27.19M	PEG	-	EPS next Q	-0.06	Inst Own	8.02%	Short Float	3.08%	Perf Quarter	-11.72%
Sales	8.38M	P/S	4.26	EPS this Y	-94.57%	Inst Trans	2.36%	Short Ratio	3.40	Perf Half Y	-41.75%
Book/sh	1.31	P/B	0.86	EPS next Y	5.03%	ROA	-57.50%	Short Interest	0.80M	Perf Year	-59.64%
Cash/sh	1.16	P/C	0.97	EPS next 5Y	-	ROE	-64.30%	52W Range	0.81 - 2.89	Perf YTD	-5.04%
Dividend Est.	-	P/FCF	-	EPS past 5Y	53.36%	ROI	-79.28%	52W High	-60.90%	Beta	0.17
Dividend TTM	-	Quick Ratio	6.63	Sales past 5Y	1653.38%	Gross Margin	227.22%	52W Low	39.51%	ATR (14)	0.11
Dividend Ex-Date	-	Current Ratio	6.63	EPS Y/Y TTM	-178.92%	Oper. Margin	-351.68%	RSI (14)	46.05	Volatility	10.77% 11.32%
Employees	14	Debt/Eq	0.00	Sales Y/Y TTM	-85.35%	Profit Margin	-324.45%	Recom	1.00	Target Price	10.50
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-216.00%	Payout	-	Rel Volume	0.22	Prev Close	1.16
Sales Surprise	69.49%	EPS Surprise	-22.11%	Sales Q/Q	-67.60%	Earnings	Nov 12 BMO	Avg Volume	234.19K	Price	1.13
SMA20	-4.26%	SMA50	0.60%	SMA200	-22.23%	Trades		Volume	52,562	Change	-2.59%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-13-24	Resumed	H.C. Wainwright	Buy	$8

Dec-19-24 08:00AM	Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy (GlobeNewswire) +18.93%
Dec-03-24 08:00AM	Opus Genetics to Host Virtual KOL Event on OPGx-LCA5 as a Treatment for LCA5-Associated Inherited Retinal Disease on December 11, 2024 (GlobeNewswire) +5.22%
Nov-14-24 06:40AM	Opus Genetics reinstated with a Buy at H.C. Wainwright (TipRanks)
Nov-12-24 08:00AM	Opus Genetics Announces Financial Results for Third Quarter 2024 and Provides Corporate Update (GlobeNewswire)
07:59AM	Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
12:00PM	Loading…
Oct-25-24 12:00PM	The RD Fund Announces Ocuphire Pharma's Acquisition of Opus Genetics (PR Newswire)
Oct-23-24 05:31PM	Ocuphire Pharma Merges with Opus Genetics, Renamed Opus Genetics (TipRanks) -12.03%
Oct-22-24 04:05PM	Ocuphire Pharma Announces Acquisition of Opus Genetics (GlobeNewswire)
Sep-30-24 08:00AM	Ocuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75% for Pharmacologically-Induced Mydriasis in Ophthalmology (GlobeNewswire)
Sep-05-24 08:43PM	UPDATE Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia (GlobeNewswire)
08:00AM	Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia (GlobeNewswire)
Aug-13-24 08:00AM	Ocuphire Pharma Announces Financial Results for Second Quarter 2024 and Provides Corporate Update (GlobeNewswire) -20.85%
Aug-08-24 08:00AM	Ocuphire Pharma to Present at Two Investor Conferences in August (GlobeNewswire) +6.10%
Jul-10-24 08:00AM	Ocuphire Pharma to Highlight APX3330 for Diabetic Retinopathy at Two Scientific Meetings in July (GlobeNewswire) +6.45%
Jun-06-24 07:57AM	Ocuphire Pharma Announces Presentations on the Development of APX3330 for Diabetic Retinopathy at Retina Meetings in June (GlobeNewswire)
01:53PM	Loading…
May-10-24 01:53PM	OCUP Stock Earnings: Ocuphire Pharma Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace) -12.24%
08:00AM	Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update (GlobeNewswire)
May-06-24 08:00AM	Ocuphire Pharma Announces Presentation on APX3330 at the ARVO 2024 Annual Meeting (GlobeNewswire)
May-03-24 08:00AM	Ocuphire Pharma to Present at the Aegis Virtual Conference (GlobeNewswire) +7.57%
Apr-22-24 08:00AM	Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting (GlobeNewswire) -8.76%
Apr-11-24 10:03AM	First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery (GlobeNewswire)
Apr-01-24 07:14AM	Ocuphire Announces the U.S. Commercial Launch of RYZUMVl (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris (GlobeNewswire) +10.95%
Mar-15-24 11:53AM	OCUP Stock Earnings: Ocuphire Pharma Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace)
Mar-09-24 01:09PM	12 Most Undervalued Biotech Stocks To Buy According To Hedge Funds (Insider Monkey)
Mar-08-24 08:00AM	Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update (GlobeNewswire) -16.39%
Mar-04-24 08:18AM	Ocuphire (OCUP) to Report Q4 Earnings: What's in the Cards? (Zacks)
Feb-23-24 08:00AM	Ocuphire Pharma to Present in the BIO CEO & Investor Conference (GlobeNewswire)
Feb-15-24 04:10PM	Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-14-24 08:00AM	Ocuphire Pharma Strengthens Leadership Team with Key Appointments (GlobeNewswire)
Feb-05-24 08:00AM	Ocuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degeneration 2024 Conference (GlobeNewswire)
04:10PM	Loading…
Jan-24-24 04:10PM	Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-11-24 07:41AM	Here's Why You Should Invest in Ocuphire Pharma (OCUP) Now (Zacks) -7.81%
Jan-04-24 08:00AM	Ocuphire Pharma Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of Phentolamine Ophthalmic Solution for the Treatment of Decreased Visual Acuity under Dim (mesopic) Light Conditions (GlobeNewswire)
Nov-30-23 08:00AM	Ocuphire Pharma Announces Presentation at Ophthalmology Innovation Summit (OIS) XIII (GlobeNewswire) +11.31%
Nov-27-23 04:38PM	Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer (GlobeNewswire)
Nov-13-23 08:00AM	Ocuphire Pharma Announces Financial Results for Third Quarter 2023 and Provides Corporate Update (GlobeNewswire)
Nov-02-23 08:00AM	Ocuphire Pharma Announces Successful End-of-Phase 2 Meeting with FDA for Oral APX3330 in Diabetic Retinopathy (GlobeNewswire)
Nov-01-23 04:52PM	Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:05AM	Ocuphire Pharma Announces Appointment of George Magrath, M.D., M.B.A., M.S., as Chief Executive Officer and Director (GlobeNewswire)
Oct-26-23 08:00AM	Ocuphire Pharma to Present at AAO 2023 and Eyecelerator Retina Showcase (GlobeNewswire)
Oct-06-23 08:00AM	Ocuphire Pharma to Present at Euretina and Retina Society Conferences in October (GlobeNewswire)
Sep-27-23 08:00AM	Viatris and Ocuphire Pharma Announce FDA Approval of RYZUMVl (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (e.g., Phenylephrine) or Parasympatholytic (e.g., Tropicamide) Agents (PR Newswire) -5.97%
08:00AM	Ocuphire Pharma and Viatris Announce FDA Approval of RYZUMVI (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (e.g., Phenylephrine) or Parasympatholytic (e.g., Tropicamide) Agents (GlobeNewswire)
Sep-11-23 09:41AM	Ocuphire Pharma to Participate in Three Upcoming Investment Bank Conferences (GlobeNewswire)
Sep-07-23 09:00AM	Ocuphire Pharma to Present at ESCRS 2023 and MODLive! Conferences in September (GlobeNewswire)
Aug-28-23 08:00AM	Abstract on ZETA-1 Study of APX3330 Receives Award at Women in Ophthalmology (WIO) Summer Symposium (GlobeNewswire)
Aug-11-23 08:00AM	Ocuphire Pharma Announces Financial Results for Second Quarter 2023 and Provides Corporate Update (GlobeNewswire)
Aug-08-23 08:00AM	Ocuphire Pharma to Present at the Canaccord 43rd Annual Growth Conference and the H.C. Wainwright Ophthalmology Conference in August (GlobeNewswire)
Jul-26-23 08:00AM	Ocuphire to Present at American Society of Retina Specialists Annual Meeting and OIS Retina Innovation Summit (GlobeNewswire)
Jul-10-23 05:19PM	Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-27-23 08:00AM	Ocuphire Presents APX3330 ZETA-1 Clinical Data in Late-Breaker Session at the American Diabetes Associations Annual Conference (GlobeNewswire)
Jun-21-23 08:00AM	Ocuphire Announces Late Breaking Presentation on APX3330 ZETA-1 Clinical Data at American Diabetes Association Annual Conference (GlobeNewswire)
Jun-12-23 08:00AM	Ocuphire Presents APX3330 ZETA-1 Data at Clinical Trials at the Summit (CTS) 2023 (GlobeNewswire)
May-24-23 04:05PM	Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.20%
May-15-23 08:00AM	Ocuphire Pharma Announces Financial Results for First Quarter 2023 and Provides Corporate Update (GlobeNewswire) -16.75%
May-02-23 08:30AM	Ocuphire Announces APX3330 and Nyxol® Data Presentations at ASCRS 2023 and Eyecelerator (GlobeNewswire) -8.31%
Apr-25-23 08:00AM	Ocuphire Provides Corporate Update and Reiterates Previous Guidance on Clinical Programs (GlobeNewswire) -7.66%
Apr-21-23 08:00AM	Ocuphire Appoints Rick Rodgers as Interim Chief Executive Officer (GlobeNewswire) -16.07%
Mar-30-23 08:00AM	Ocuphire Pharma Announces Financial Results for Fourth Quarter and Year Ended 2022 and Provides Corporate Update (GlobeNewswire) +6.39%
Mar-23-23 08:00AM	Ocuphire Announces APX3330 and Nyxol® Data Presentations at ARVO 2023 Annual Meeting (GlobeNewswire)
Feb-16-23 08:30AM	Ocuphire Announces APX3330 Phase 2 Data Presentations at Retina Meetings (GlobeNewswire)
Feb-13-23 08:00AM	Ocuphire Announces FDA Acceptance of New Drug Application and PDUFA Date of September 28, 2023 for Nyxol® Eye Drops for Reversal of Mydriasis (GlobeNewswire) +14.94%
Jan-25-23 04:01PM	Ocuphire Announces Topline Results from ZETA-1 Phase 2 Trial of Oral APX3330 in Diabetic Retinopathy and Plans for End-of-Phase 2 Meeting with FDA (GlobeNewswire) -19.95%
Jan-09-23 07:00AM	Ocuphire Pharma Announces First Patient Enrolled in VEGA-2 Pivotal Phase 3 Trial of Nyxol® in Presbyopia (GlobeNewswire) +7.26%
Dec-06-22 06:00AM	Ocuphire Pharma Announces Submission of New Drug Application to FDA for Nyxol® Eye Drops for Reversal of Mydriasis (GlobeNewswire) -5.28%
Dec-05-22 08:30AM	Stock Pitch World Cup(TM), Educational Panels and 49 Companies to Present at the Planet MicroCap Showcase: VIRTUAL on December 6-8, 2022 (ACCESSWIRE)
Nov-21-22 08:00AM	Ocuphire to Present at Five Upcoming Investor/Industry Conferences (GlobeNewswire)
Nov-07-22 04:05PM	Ocuphire Pharma Enters into a Global License Agreement for Development and Commercialization of Nyxol Eye Drops for Reversal of Mydriasis, Presbyopia and Night Vision Disturbances (GlobeNewswire) -5.02% +19.71%
Nov-04-22 04:30PM	Ocuphire Pharma Announces Financial Results for Third Quarter 2022 and Provides Corporate Update (GlobeNewswire)
Nov-02-22 08:10AM	Ocuphire Announces Peer-Reviewed Publication in BMC Ophthalmology for Nyxol® and Strategic Partnership with American Society of Ophthalmic Administrators (ASOA) (GlobeNewswire) -6.03%
Oct-24-22 08:56AM	Ocuphire Announces Six Poster Presentations on Nyxol and APX3330 at the American Academy of Optometry Annual Meeting (GlobeNewswire)
Oct-07-22 07:00AM	Ocuphire Pharma to Present at the MicroCap Rodeo Windy City Roundup 2022 Conference (GlobeNewswire)
Oct-06-22 09:27AM	Ocuphire Pharma Hosting Key Opinion Leader Event on Oral APX3330 for Diabetic Eye Disease (GlobeNewswire)
Sep-29-22 08:00AM	Ocuphire Expands Medical Advisory Board with Seven New KOLs and Strengthens Leadership Team (GlobeNewswire)
Sep-27-22 09:05AM	60+ Companies to Present at the 2nd Annual MicroCap Rodeo - Windy City Roundup Conference on October 12th - 13th, 2022 in Chicago (ACCESSWIRE)
Sep-15-22 07:00AM	Ocuphire Announces Upcoming Presentations at European Forum 2022, Eyecelerator@AAO 2022 and the American Academy of Ophthalmology 2022 Annual Meeting (GlobeNewswire)
Sep-12-22 08:00AM	Ocuphire Pharma Receives PDFUA Fee Waiver for Nyxol New Drug Application from FDA (GlobeNewswire)
Sep-08-22 08:00AM	Ocuphire Pharma Announces Last Patient Completes Final Visit in ZETA-1 Phase 2b 24-Week Trial of Oral APX3330 in Diabetic Retinopathy (GlobeNewswire)
Sep-06-22 09:00AM	Ocuphire Pharma to Present at The H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-12-22 07:00AM	Ocuphire Pharma Announces Financial Results for the Second Quarter 2022 and Provides Corporate Update (GlobeNewswire) -8.96%
Aug-08-22 01:16PM	We're Keeping An Eye On Ocuphire Pharma's (NASDAQ:OCUP) Cash Burn Rate (Simply Wall St.)
07:00AM	Ocuphire Pharma Announces Upcoming Presentations at Two Conferences in August (GlobeNewswire)
Aug-03-22 08:00AM	Ocuphire Extends U.S. Patent Protection for Late-Stage Drug Candidate Nyxol® for Reversal of Mydriasis by Five More Years into 2039 with New Patent Issuance (GlobeNewswire)
Jul-07-22 08:00AM	Ocuphire Announces Late-Breaking Paper for Nyxol for Reversal of Dilation Indication at Annual ASRS Meeting and Five More Presentations at Conferences in July (GlobeNewswire)
Jun-29-22 09:00AM	Ocuphire Granted New U.S. Patent for Late-Stage Oral Drug Candidate APX3330 for Use in Diabetics and Announces New Peer-Reviewed APX3330 Publication (GlobeNewswire)
Jun-24-22 08:59AM	BlackBerry Earnings Reveal Smaller Than Expected Loss (Barrons.com) -5.94%
Jun-08-22 08:00AM	Ocuphire to Present New Interim Masked Safety Data for Oral APX3330 in Diabetics at Annual Macula Society Meeting (GlobeNewswire)
May-19-22 07:00AM	Ocuphire Announces Positive Topline Results from LYNX-1 Phase 3 Trial Evaluating Nyxol® Eye Drops for Night Vision Disturbances (GlobeNewswire)
May-13-22 08:00AM	Ocuphire Pharma Announces Financial Results for First Quarter 2022 and Provides Corporate Update (GlobeNewswire) +8.04%
May-11-22 08:00AM	Ocuphire Pharma Announces Upcoming Presentations at the Retina World Congress, Clinical Trials at the Summit, and the H.C. Wainwright Global Investment Conference (GlobeNewswire)
Apr-28-22 07:00AM	Ocuphire Completes Last Clinical Trial Supporting the Planned 2022 NDA Submission with the Announcement of Positive Results from MIRA-4 Pediatric Safety Trial Evaluating Nyxol® for Reversal of Mydriasis (GlobeNewswire)
Apr-26-22 09:00AM	Ocuphire Announces Upcoming Clinical Presentations at ARVO 2022 Medical Meeting and MODLive! 2022 (GlobeNewswire) -6.27%
Apr-19-22 08:00AM	Ocuphire Appoints Jay Pepose, M.D., Ph.D., as Chief Medical Advisor and Announces Upcoming Presentations at ASCRS 2022 and Eyecelerator (GlobeNewswire)
Apr-06-22 08:00AM	Ocuphire Pharma to Present at Wet AMD & DME Drug Development Summit in Boston, MA (GlobeNewswire)
Mar-29-22 07:00AM	Ocuphire Announces Positive Topline Results from MIRA-3 Phase 3 FDA Registration Trial for Nyxol® in the Reversal of Mydriasis (GlobeNewswire) -16.24%
Mar-24-22 08:00AM	Ocuphire Announces Financial Results for the Fourth Quarter and Year Ended December 31, 2021 and Provides Corporate Update (GlobeNewswire) +5.57%
Mar-16-22 07:30AM	Ocuphire Completes Enrollment of Over 100 Subjects in 24-Week ZETA-1 Phase 2b Trial of Oral APX3330 for the Treatment of Diabetic Retinopathy (GlobeNewswire)
Mar-10-22 09:27AM	Ocuphire Pharma to Present at Oppenheimer Annual Healthcare Conference (GlobeNewswire)
Mar-08-22 08:00AM	Ocuphire Completes Enrollment in MIRA-4 Pediatric Safety Trial Evaluating Nyxol® for Reversal of Mydriasis (GlobeNewswire)

Opus Genetics, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Farmington Hills, MI.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Magrath George	Chief Executive Officer	Dec 26 '24	Buy	0.98	100,000	97,600	599,150	Dec 30 04:26 PM
YERXA BENJAMIN R	President	Nov 21 '24	Buy	0.98	10,000	9,834	342,800	Nov 25 04:18 PM
Magrath George	Chief Executive Officer	Nov 15 '24	Buy	1.01	90,294	91,215	483,244	Nov 19 04:08 PM
Magrath George	Chief Executive Officer	Nov 18 '24	Buy	1.02	9,706	9,943	492,950	Nov 19 04:08 PM
Jayagopal Ashwath	Chief Scientific & Dev. Ofc.	May 22 '24	Buy	1.76	3,500	6,178	78,500	May 24 04:07 PM
Magrath George	Chief Executive Officer	May 17 '24	Buy	1.75	5,000	8,772	430,000	May 21 04:18 PM
SCHACHLE JOSEPH K	Chief Operating Officer	Mar 21 '24	Buy	2.05	2,000	4,100	2,000	Mar 25 04:44 PM
Jhaveri Nirav S.	Chief Financial Officer	Mar 21 '24	Buy	2.10	10,000	21,000	150,000	Mar 25 04:40 PM
Magrath George	Chief Executive Officer	Mar 18 '24	Buy	1.96	25,000	49,050	425,000	Mar 20 04:18 PM

Open in Screener

CLSD

Clearside Biomedical Inc

Jan 17 • 04:00PM ET

0.9299

Dollar change +0.0049
Percentage change 0.53	%

Healthcare • Biotechnology • USA • NASD

CLSD Clearside Biomedical Inc daily Stock Chart

Peers: EYPT VKTX OCUL CARA ALDX RIGL IRD AKBA BYSI

| Held by: VTI VXF IWC

Index	-	P/E	-	EPS (ttm)	-0.45	Insider Own	15.29%	Shs Outstand	74.75M	Perf Week	-5.11%
Market Cap	70.53M	Forward P/E	-	EPS next Y	-0.45	Insider Trans	0.32%	Shs Float	64.24M	Perf Month	-7.93%
Income	-31.88M	PEG	-	EPS next Q	-0.10	Inst Own	15.81%	Short Float	1.15%	Perf Quarter	-16.97%
Sales	7.70M	P/S	9.16	EPS this Y	11.86%	Inst Trans	-19.27%	Short Ratio	2.29	Perf Half Y	-19.14%
Book/sh	-0.47	P/B	-	EPS next Y	3.67%	ROA	-100.27%	Short Interest	0.74M	Perf Year	-30.60%
Cash/sh	0.31	P/C	2.99	EPS next 5Y	-	ROE	-	52W Range	0.80 - 2.12	Perf YTD	-2.12%
Dividend Est.	-	P/FCF	-	EPS past 5Y	27.88%	ROI	-215.23%	52W High	-56.14%	Beta	2.23
Dividend TTM	-	Quick Ratio	4.49	Sales past 5Y	240.58%	Gross Margin	97.83%	52W Low	16.09%	ATR (14)	0.06
Dividend Ex-Date	-	Current Ratio	4.49	EPS Y/Y TTM	26.05%	Oper. Margin	-319.98%	RSI (14)	42.75	Volatility	5.55% 6.46%
Employees	30	Debt/Eq	-	Sales Y/Y TTM	248.39%	Profit Margin	-413.83%	Recom	1.00	Target Price	6.00
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	31.17%	Payout	-	Rel Volume	0.49	Prev Close	0.93
Sales Surprise	698.46%	EPS Surprise	19.55%	Sales Q/Q	20.84%	Earnings	Nov 12 AMC	Avg Volume	323.98K	Price	0.93
SMA20	-1.63%	SMA50	-7.83%	SMA200	-19.70%	Trades		Volume	157,831	Change	0.53%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-21-24	Initiated	Chardan Capital Markets	Buy	$6
Jun-25-24	Initiated	Oppenheimer	Outperform	$5
Dec-15-21	Resumed	Wedbush	Outperform	$19 → $9
Jul-29-21	Initiated	H.C. Wainwright	Buy	$10
May-13-20	Initiated	ROTH Capital	Buy	$8
Aug-09-19	Downgrade	Needham	Buy → Hold
Nov-05-18	Downgrade	Stifel	Buy → Hold
Nov-05-18	Downgrade	JP Morgan	Overweight → Underweight
Nov-05-18	Downgrade	Cowen	Outperform → Market Perform
Mar-06-18	Reiterated	Needham	Buy	$18 → $22
May-25-17	Initiated	JMP Securities	Mkt Outperform	$21
Feb-24-17	Initiated	JP Morgan	Overweight	$19
Nov-10-16	Reiterated	Needham	Buy	$16 → $24
Oct-24-16	Reiterated	Stifel	Buy	$13 → $23

Show Previous Ratings

Dec-20-24 07:16AM	Clearside announces publication of insights on drug development, regulation (TipRanks) -6.20%
05:29AM	Analyst Sees 500% Upside for This Pharmaceutical Penny Stock (GuruFocus.com)
Dec-19-24 07:05AM	Clearside Biomedical Announces Publication of Critical Insights into Retinal Drug Development in the Peer-Reviewed Scientific Journal, Eye (GlobeNewswire)
Dec-12-24 09:55AM	Here's Why Clearside Biomedical (CLSD) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Nov-25-24 07:05AM	Clearside Biomedical Extends Global Footprint with Numerous Presentations at Medical Meetings in Asia, Europe and the United States (GlobeNewswire)
12:00PM	Loading…
Nov-15-24 12:00PM	All You Need to Know About Clearside Biomedical (CLSD) Rating Upgrade to Buy (Zacks) -5.71%
Nov-13-24 02:17AM	Clearside Biomedical Inc (CLSD) Q3 2024 Earnings Call Highlights: Promising Clinical Trial ... (GuruFocus.com)
Nov-12-24 06:05PM	Clearside Biomedical, Inc. (CLSD) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Clearside Biomedical Announces Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-11-24 07:23AM	Clearside Biomedical Inc (CLSD) Q3 2024 Earnings Report Preview: What to Look For (GuruFocus.com)
Nov-08-24 03:56AM	Santen, Arctic Vision sign deal for ARVN001 to treat UME (Pharmaceutical Technology)
Nov-07-24 09:05AM	Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular Edema (GlobeNewswire)
Nov-06-24 07:05AM	Clearside Biomedical to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference (GlobeNewswire)
Nov-04-24 07:05AM	Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of Directors (GlobeNewswire)
Oct-31-24 07:05AM	Clearside Biomedical to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Tuesday, November 12, 2024 (GlobeNewswire)
07:05AM	Loading…
Oct-22-24 07:05AM	Clearside Biomedical's Positive ODYSSEY Wet AMD Data and Suprachoroidal Injection Platform Highlighted in Presentations at Multiple Events During AAO 2024 Annual Meeting (GlobeNewswire) -10.23%
Oct-10-24 08:57AM	Morning Movers: Arcadium Lithium surges after deal to be acquired (TipRanks)
Oct-09-24 10:22AM	Clearside Biomedical's Investigational Drug For Vision Loss Hits Primary Goals In Mid-Stage Study (Benzinga) -11.49%
06:30AM	Clearside Biomedical Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes (GlobeNewswire)
Aug-27-24 07:05AM	Clearside Biomedical Announces Completion of Final Participant Visit in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD (GlobeNewswire)
Aug-15-24 09:35AM	After Plunging -15.7% in 4 Weeks, Here's Why the Trend Might Reverse for Clearside Biomedical (CLSD) (Zacks)
Aug-12-24 05:25PM	Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Clearside Biomedical Announces Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-08-24 07:05AM	Clearside Biomedical to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference (GlobeNewswire)
Aug-05-24 10:00AM	Clearside Biomedical, Inc. (CLSD) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Aug-01-24 07:05AM	Clearside Biomedical to Report Second Quarter 2024 Financial Results on Monday, August 12, 2024 (GlobeNewswire)
Jul-29-24 04:05PM	Clearside Biomedical's Partner Arctic Vision Reports Positive Topline Results from Phase 3 Clinical Trial of ARCATUS for Suprachoroidal Use in Uveitic Macular Edema Patients in China (GlobeNewswire)
Jul-22-24 12:00PM	Clearside Biomedical Opens Registration for Suprachoroidal Delivery KOL Webinar to Be Held on Wednesday, July 24, 2024 at 8:00 am ET (GlobeNewswire)
Jul-11-24 07:05AM	Clearside Biomedical Appoints Dr. Glenn Yiu to its Scientific Advisory Board (GlobeNewswire)
Jun-27-24 07:05AM	Clearside Biomedical to Host Virtual Key Opinion Leader Event on the Use and Versatility of Suprachoroidal Drug Delivery (GlobeNewswire) +5.79%
07:05AM	Loading…
Jun-12-24 07:05AM	Clearside Biomedical's Leadership in Suprachoroidal Delivery Featured in Multiple Presentations at the Clinical Trials at the Summit Meeting (GlobeNewswire)
May-21-24 07:05AM	Clearside Biomedical Announces Publication of Consensus Guidelines for Drug Delivery via Suprachoroidal Space (SCS ) Injection in Leading Peer-Reviewed Industry Journal, RETINA (GlobeNewswire) +12.03%
May-13-24 08:20AM	HC Wainwright Adjusts Price Target on Clearside Biomedical to $5 From $6, Keeps Buy Rating (MT Newswires)
May-10-24 02:15PM	Q1 2024 Clearside Biomedical Inc Earnings Call (Thomson Reuters StreetEvents) -7.41%
11:56AM	Clearside Biomedical, Inc. (NASDAQ:CLSD) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 06:55PM	Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +6.30%
04:05PM	Clearside Biomedical Announces First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
May-08-24 04:15PM	Clearside Biomedical to Participate in Fireside Chat at the Citizens JMP Life Sciences Conference (GlobeNewswire)
Apr-30-24 07:05AM	Clearside Biomedical to Report First Quarter 2024 Financial Results and Provide Corporate Update on Thursday, May 9, 2024 (GlobeNewswire)
Apr-16-24 07:05AM	Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors (GlobeNewswire) -10.85%
Apr-02-24 07:05AM	Clearside Biomedical to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire) -11.39%
Mar-18-24 07:05AM	Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer (GlobeNewswire) -8.77%
Mar-13-24 08:30AM	Clearside Biomedical, Inc. (NASDAQ:CLSD) Q4 2023 Earnings Call Transcript (Insider Monkey)
06:38AM	Q4 2023 Clearside Biomedical Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-12-24 05:35PM	Clearside Biomedical Inc (CLSD) Reports Significant Licensing Revenue Growth in Q4 and Full ... (GuruFocus.com) -18.81%
04:05PM	Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-06-24 02:25PM	These 2 Strong Buy Penny Stocks Could Surge Over 200%, Say Analysts (TipRanks) +8.63%
Feb-29-24 07:05AM	Clearside Biomedical to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on Tuesday, March 12, 2024 (GlobeNewswire)
Feb-25-24 01:37PM	7 Biotech Penny Stocks on the Verge of Clinical Trial Victory (InvestorPlace)
Feb-07-24 08:00AM	Clearside Biomedical Announces Pricing of $15 Million Registered Direct Offering (GlobeNewswire)
Dec-14-23 07:05AM	Clearside Biomedical Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD (GlobeNewswire)
Nov-14-23 09:11AM	Clearside Biomedical, Inc. (NASDAQ:CLSD) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-13-23 04:05PM	Clearside Biomedical Announces Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-08-23 07:05AM	Clearside Biomedical to Participate in Fireside Chat at the Stifel 2023 Healthcare Conference (GlobeNewswire) -9.65%
Nov-07-23 04:20PM	Clearside Biomedical's Versatile Suprachoroidal Injection Platform Highlighted in Four Ophthalmic Indications in Clinical Data Presentations at AAO 2023 Annual Meeting (GlobeNewswire)
Nov-03-23 12:00PM	BioCryst and Clearside Biomedical Enter Partnership to Develop Avoralstat for Diabetic Macular Edema Using Clearside's Proprietary SCS Microinjector (GlobeNewswire) +19.39%
Nov-02-23 07:05AM	Clearside Biomedical Announces Presentations at the American Academy of Ophthalmology 2023 Annual Meeting (GlobeNewswire)
Nov-01-23 07:05AM	Clearside Biomedical Completes Recruitment in ODYSSEY Phase 2b Clinical Trial of CLS-AX in Wet AMD (GlobeNewswire) +5.30%
Oct-31-23 07:05AM	Clearside Biomedical to Report Third Quarter 2023 Financial Results and Provide Corporate Update on Monday, November 13, 2023 (GlobeNewswire) +5.17%
Oct-26-23 12:24AM	3 Cheap Stocks to Buy Under $1 in October 2023 (InvestorPlace) -5.28%
Oct-16-23 07:05AM	Clearside Biomedical Positive OASIS and Extension Study Data Presented at The Retina Society 56th Annual Scientific Meeting (GlobeNewswire)
Oct-04-23 09:00AM	Clearside Biomedical Announces Advancement of XIPERE in Asia-Pacific for Suprachoroidal Treatment of Uveitic Macular Edema as Partner Arctic Vision Completes Enrollment in Phase 3 Clinical Trial in China (GlobeNewswire)
Oct-03-23 04:35PM	Clearside Biomedical to Participate in a Panel Discussion at the JonesTrading 2023 Healthcare Summit (GlobeNewswire)
Sep-19-23 07:05AM	Clearside Biomedical to Participate in Panel Discussion at the Cantor Global Healthcare Conference (GlobeNewswire)
Aug-14-23 04:05PM	Clearside Biomedical Announces Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) -6.60%
Aug-02-23 04:30PM	Clearside Biomedical to Participate in Upcoming Investor Conferences in August 2023 (GlobeNewswire) -5.26%
Aug-01-23 07:05AM	Clearside Biomedical to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Monday, August 14, 2023 (GlobeNewswire)
Jul-31-23 07:05AM	Clearside Biomedical Highlights Excellent Safety Profile of CLS-AX and Potential for Extended Duration of Effect in Data Presentation at the American Society of Retina Specialists 41st Annual Scientific Meeting (GlobeNewswire)
Jul-20-23 07:05AM	Clearside Biomedicals Suprachoroidal Injection Platform to be Featured at Upcoming ASRS and OIS Scientific Meetings (GlobeNewswire)
Jul-11-23 04:05PM	Clearside Biomedical CEO George Lasezkay to Present at the SHARE Series Investor Event on Monday, July 17, 2023 (GlobeNewswire)
Jul-10-23 07:05AM	Clearside Biomedical Asia-Pacific Partner Arctic Vision Announces the Acceptance in Australia of its New Drug Application for Suprachoroidal Use of Arcatus® for the Treatment of Uveitic Macular Edema (GlobeNewswire)
Jun-29-23 09:50AM	We're Keeping An Eye On Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Rate (Simply Wall St.)
Jun-01-23 07:05AM	Clearside Biomedical Opens Enrollment in ODYSSEY Phase 2b Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD (GlobeNewswire)
May-11-23 08:25AM	Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -6.90%
07:05AM	Clearside Biomedical Announces First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
May-09-23 04:30PM	Clearside Biomedical to Participate in a Fireside Chat at the JMP Securities Life Sciences Conference (GlobeNewswire) +7.41%
May-02-23 07:05AM	Clearside Biomedical to Report First Quarter 2023 Financial Results and Provide Corporate Update on Thursday, May 11, 2023 (GlobeNewswire)
Apr-27-23 07:05AM	Clearside Biomedical Presents Compelling Data at The Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting (GlobeNewswire)
Apr-18-23 07:05AM	Clearside Biomedical Announces Plans for ODYSSEY Phase 2b Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD (GlobeNewswire)
Apr-12-23 07:05AM	Clearside Biomedical to Participate in a Fireside Chat at the 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire) -10.48%
Apr-09-23 09:42AM	Clearside Biomedical (NASDAQ:CLSD) adds US$12m to market cap in the past 7 days, though investors from five years ago are still down 88% (Simply Wall St.)
Apr-05-23 07:05AM	Clearside Biomedical Enhances Scientific Advisory Board with the Appointment of Two Distinguished Retinal Physicians (GlobeNewswire) -8.89%
Mar-11-23 03:14AM	Clearside Biomedical, Inc. (NASDAQ:CLSD) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-09-23 06:35PM	Clearside Biomedical, Inc. (CLSD) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -9.24%
04:05PM	Clearside Biomedical Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-23-23 07:05AM	Clearside Biomedical to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on Thursday, March 9, 2023 (GlobeNewswire) -5.26%
Feb-21-23 07:05AM	Clearside Biomedical Announces Positive Data Presentations on CLS-AX OASIS Clinical Trial and Use of SCS Microinjector® Presented at the Angiogenesis and Macula Society Annual Meetings (GlobeNewswire)
Feb-07-23 07:05AM	Clearside Biomedical OASIS Data to be Presented at Multiple Upcoming Medical Meetings in February 2023 (GlobeNewswire)
Feb-06-23 07:30AM	Clearside Biomedical Announces Leadership Team Update (GlobeNewswire)
Feb-02-23 01:18PM	Clearside Biomedical Touts Encouraging Durable Data From Investigational Candidate For Vision Disorder (Benzinga)
07:05AM	Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study with Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD (GlobeNewswire)
Dec-22-22 09:52AM	2 Strong Buy Penny Stocks That Could Go Boom (TipRanks) +8.00%
05:05AM	Companies Like Clearside Biomedical (NASDAQ:CLSD) Can Afford To Invest In Growth (Simply Wall St.)
Nov-22-22 07:05AM	Clearside Biomedical to Participate in Multiple Upcoming Investor and Ophthalmology Conferences in November and December 2022 (GlobeNewswire)
Nov-11-22 05:26AM	Clearside Biomedical Third Quarter 2022 Earnings: Beats Expectations (Simply Wall St.)
Nov-10-22 01:24PM	Analyst Bumps Up Clearside Biomedical Target Price After Encouraging Trial Data (Benzinga)
07:05AM	Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2022 Healthcare Conference (GlobeNewswire)
Nov-09-22 09:05AM	Clearside Biomedical, Inc. (CLSD) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -8.57%
07:15AM	Clearside Biomedical Announces Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
07:05AM	Clearside Biomedical Announces Positive Results in Safety, Durability and Biologic Effect in OASIS Phase 1/2a Clinical Trial of Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD Patients (GlobeNewswire)

Clearside Biomedical, Inc. is a biopharmaceutical company, which delivers therapies to the back of the eye through the suprachoroidal space. Its pipeline include CLS-AX, Integrin Inhibitor, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F. Edelhauser in May 2011 and is headquartered in Alpharetta, GA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Chong Ngai Hang Victor	Chief Medical Officer	Nov 01 '24	Buy	1.00	36,500	36,500	100,000	Nov 04 04:15 PM
Chong Ngai Hang Victor	Chief Medical Officer	Jun 24 '24	Buy	1.06	23,500	24,910	63,500	Jun 24 04:38 PM
YERXA BENJAMIN R	Director	May 15 '24	Buy	1.31	7,813	10,235	17,957	May 15 05:28 PM
Gibney Anthony S	Director	Apr 18 '24	Buy	1.30	93,290	121,277	100,000	Apr 19 09:45 AM
Gibney Anthony S	Director	Apr 17 '24	Buy	1.25	6,710	8,388	6,710	Apr 19 09:45 AM
Chong Ngai Hang Victor	CHIEF MEDICAL OFFICER	Mar 20 '24	Buy	1.60	30,000	48,000	30,000	Mar 20 04:30 PM
WHITMORE BRADFORD T	10% Owner	Feb 07 '24	Buy	1.35	444,444	599,999	4,495,034	Feb 09 01:00 PM
LASEZKAY GEORGE M	CEO	Jan 19 '24	Sale	1.27	18,000	22,860	466,577	Jan 19 06:26 PM
Deignan Charles A.	Chief Financial Officer	Jan 19 '24	Sale	1.28	12,900	16,512	384,662	Jan 19 06:25 PM

IRD

Opus Genetics Inc

CLSD

Clearside Biomedical Inc

Upgrade your FINVIZ experience